Effect of urine urea nitrogen and protein intake adjusted by using the estimated urine creatinine excretion rate on the antiproteinuric effect of angiotensin II type I receptor blockers

What Was Tested

The paper reports a study of Angiotensin II, published as a randomized controlled trial.

Who Took Part

PubMed indexes the participants as young adults, adults, middle-aged adults and older adults, both men and women.

The researchers estimated the urine excretion rate of parameters in a day, adjusted by using the equation for estimating urine creatinine excretion, and analyzed the effect of urine urea nitrogen (UUN), as well as estimating protein intake on the level of albuminuria in hypertensive patients with chronic kidney disease.

How the Study Was Run

In design terms this was a randomized and open-label study.

Because people in this Angiotensin II study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Being open-label, the Angiotensin II study did not mask who received what.

This is a subanalysis of data from an open-label, case-controlled, randomized clinical trial on education about low-salt diets (NCT01552954).

What Was Measured

The subject headings attached to it are Albumins, Albuminuria, Angiotensin II, Angiotensin II Type 1 Receptor Blockers, Creatinine, Diet and Dietary Proteins.

Author keywords: Chronic kidney disease, Protein intake and Urine urea nitrogen.

What This Means in Plain Language

The paper is a randomized and open-label study of Angiotensin II.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2015 (Nutrition (Burbank, Los Angeles County, Calif.)), a journal based in United States.

More context: the Angiotensin II compound page, all human trials.